---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-110019"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:10:33.109345+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics Phase 3 EBO-301 misses primary endpoint; outlines boron pipeline milestones, cash runway into 2028

## Summary
- Phase 3 portion of EBO-301 (n=97) did not meet primary endpoint of QOL-B respiratory domain improvement at month 6.
- Cash, cash equivalents & investments $78.5M as of March 31, 2025; cash runway extended into 2028.
- Initiated start up for Phase 1 study of AN2-502998 for chronic Chagas disease, expected completion in 2H25.
- Plans Phase 2 study for epetraborole in melioidosis in 2H25 aiming to reduce ~40% mortality.
- First oncology compounds from boron platform on track for development in 2H25, targeting ENPP1, PI3Kα.

## SEC filing metadata
- accession: 0001193125-25-110019
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312525110019/0001193125-25-110019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312525110019/d116214d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-110019
- JSON: https://secwatch.observer/filing/0001193125-25-110019.json
- Plain text: https://secwatch.observer/filing/0001193125-25-110019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.